About Us

Built by clinical operations, clinical development and AI experts

Aico reimagines execution of modern clinical trials

Our Story

Clinical development remains constrained by manual workflows and reactive operations—a critical inefficiency in an era of scientific acceleration

Founded by veterans of drug development and AI, Aico emerged from two decades of operational insight. Cofounder Samantha’s experience across sponsors and CROs revealed that timeline delays are predominantly executional, not scientific.

What if trial execution could be driven by an adaptive AI system—one that understands protocol logic, operational context, and real-time data?

AICRO has emerged to meet this need. A vendor-agnostic, multi-agent AI architecture trained on
proprietary clinical datasets and protocol logic. The system:
  • Orchestrates cross-functional trial workflows
  • Anticipates and mitigates bottlenecks preemptively
  • Delivers interpretable, audit-ready decision support

In early real-world deployments, our system has achieved 50% reductions in clinical trial timelines.

Driven by AI, grounded in expertise

Design for intelligence
 

We build systems that learn, adapt, and support smarter decisions.

Speed with integrity
 

Acceleration only matters if it’s rooted in trust, quality, and compliance.

User-obsessed simplicity
 

We reduce complexity by focusing on what matters most to our users.

Ownership & iteration
 

We move fast, measure results, learn, and evolve.

Our Team

Our leadership unites veteran drug-development executives, repeat entrepreneurs, and elite AI scientists. With extensive experience spanning the pharmaceutical industry and CRO, our cofounders demonstrated success in driving clinical development of numerous innovative therapeutic products across diverse technology platforms.

That operating discipline is personified by cofounder Samantha, who spent twenty years uncovering and eliminating hidden inefficiencies in clinical operations. Her obsession with speed and precision inspired the company’s AI-first, vendor-agnostic approach: a multi-agent system trained on proprietary industry know-how and live study data that slashes trial timelines by up to 50 percent in early pilots.